Safety and Efficacy of Evolocumab in Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05697185

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Second Affiliated Hospital of Guangxi Medical University (from the registry)
Registry
  • NCT NCT05697185
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05697185. Randomized; single masking; primary purpose treatment. Start 2023-02-01 (anticipated); primary completion 2024-02-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Evolocumab in Ischemic Stroke
Acronym
SEEIS
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Evolocumab
Lead sponsor
Second Affiliated Hospital of Guangxi Medical University (class: other)

Record details

Record id
cardio:ct-nct05697185
Content hash
129ef45c1543eb0f79aa4515e177234689f293d5360bb34796d4e01873c2ab3b